Expression of topoisomerase IIα in the G0/G1 cell cycle phase of fresh leukemic cells

Leukemia Research

Volumn 25, Issue 11, 2001, Pages 961-966

  Uggla, Bertil ^a   Möllgård, Lars ^b   Ståhl, Elisabet ^a   Mossberg, Lise Lott ^a   Karlsson, Mats G ^a   Paul, Christer ^b,c   Tidefelt, Ulf ^a,c  

^a ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Acute leukemia; Cell cycle; Drug resistance; Flow cytometry; Topoisomerase II

Indexed keywords

CYTOSTATIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); PROTEIN SUBUNIT; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; TUMOR ANTIGEN;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL SEPARATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONONUCLEAR CELL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REMISSION; ACUTE DISEASE; CASE CONTROL STUDY; CELL CYCLE; ENZYMOLOGY; LEUKEMIA; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; CELL CYCLE; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FLOW CYTOMETRY; G0 PHASE; G1 PHASE; HUMANS; LEUKEMIA; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0034740798     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00062-5     Document Type: Article

References (27)

1. Multidrug resistance in leukemia
2. DNA topoisomerases
3. Topoisomerase IIα and topoisomerase IIβ genes: Characterization and mapping to human chromosomes 17 and 3, respectively
4. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
5. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and the 180 kilodalton forms of topoisomerase II in NIH-3T3 cells
6. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle
7. DNA topoisomerase poisons as antitumor drugs
8. Antitopoisomerase drug action and resistance
9. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines
10. Differential expression of DNA topoisomerases IIα and -β in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4
11. Relationship of DNA topoisomerase IIα and β expression to cytotoxicity of antineoplastic agents in human acute lymphoblastic leukemia cell lines
12. Reduced topoisomerase II activity in human CEM leukemia cells selected for resistance to mitoxantrone
13. Altered gene expression in human leukemia K562 cells selected for resistance to etoposide
14. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia
15. Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines
16. Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias
17. Expression of MDR1, GST-π and topoisomerase II as an indicator of clinical response to adriamycin
18. Correlation between p53, c-erbB2 and topoisomerase IIα expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: Prognostic implications
19. Topoisomerase IIα expression in acute myeloid leukemia and its relationship to clinical outcome
20. Clinical resistance to topoisomerase-targeted drugs
21. Predictive value of topoisomerase IIα and other prognostic factors for epirubicin chemotherapy in advanced breast cancer
22. Immunohistochemical and two-parameter flow cytometrc studies of DNA topoisomerase IIα in human epithelial ovarian carcinoma and germ cell tumor
23. Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170 kD and 180 kD forms of topoisomerase II
24. Cell cycle control and cancer
25. p53 involvement in control of G2 exit of the cell cycle: Role in DNA damage-induced apoptosis
26. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts
27. Topoisomerase IIα promoter trans-activation early in monocytic differentiation of HL-60 human leukemia cells